Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOHARM MTD
NCT07708714Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- May 2026
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 cohorts), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Composite measure of organ damage at 48 months. Started May 2026; status: recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT07708714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708714.